加载中
NASDAQHealthcareBiotechnology
最新数据
US$11.525
−US$0.085 · -0.73%
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
常规交易时段
US$11.525
−US$0.085 · -0.73%
盘中时间采用ET。市场数据可能有所延迟。
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
日内区间
当前US$11.525
52周区间
当前US$11.525
盘中时间采用ET。市场数据可能有所延迟。
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
日内区间
当前US$11.525
52周区间
当前US$11.525
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$42.00
上涨空间 264.43%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1817.83万0.00%2.3万亿 USD0.03%US$381.21-0.19%
iShares Russell 2000 ETFIWM1404.73万0.02%787.4亿 USD0.19%US$277.93-0.36%
State Street SPDR S&P Biotech ETFXBI1396.66万0.14%98.74亿 USD0.35%US$151.26-1.63%
Vanguard Morningstar Small-Cap ETFVB1314.07万0.01%1853亿 USD0.03%US$288.12-0.47%
Vanguard Morningstar Small-Cap Growth ETFVBK750.33万0.02%447亿 USD0.05%US$340.58-1.21%
Vanguard Extended Market ETFVXF742.04万0.01%954亿 USD0.05%US$233.51-0.63%
Vanguard Russell 2000 ETFVTWO408.68万0.02%180亿 USD0.06%US$112.27-0.35%
iShares Russell 2000 Growth ETFIWO336.97万0.02%139.17亿 USD0.24%US$353.65-0.88%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
